ADC TOXICITY ATLAS
AtlasPayloads and LinkersPayloadsTargetsMethods
← Payloads & linkers
Linker

MC-vc-PAB (vedotin)

Cleavable

[H]OC([H])([H])c1c([H])c([H])c(N([H])C(=O)[C@@]([H])(N([H])C(=O)[C@@]([H])(N([H])C(=O)C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])N2C(=O)C([H])=C([H])C2=O)C([H])(C([H])([H])[H])C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=O)N([H])[H])c([H])c1[H]
Physicochemistry

Properties

MW
572.663 Da
TPSA
200.03 Ų
xLogP
0.6769
Formula
C28H40N6O7
Cleavage
Cleavable
Attachment
Cysteine (interchain)
23 agents

ADCs built on this linker

Agent · target
Ocular
Hepatic
Neutrop.
Thrombo.
Anemia
GI
ILD
Neuro.
Tisotumab vedotinF3
55
34
16
41
33
2
38
Iladatuzumab vedotinCD79B
47
8
27
20
5
20
MYTX-011MET
47
33
0
0
5
36
36
Enfortumab vedotinNECTIN4
40
75
27
28
35
3
53
Sirtratumab vedotinSLITRK6
29
37.6
19.4
Telisotuzumab vedotinMET
25
41
10
14
35
15
10
51
Samrotamab vedotin (ABBV-085)LRRC15
24.4
19
31
Lifastuzumab vedotinSLC34A2
20
22
73
61
32
49
34
61
DLYE5953A (RG-7841)LY6E
10
16
13
12
38
35
Pinatuzumab vedotinCD22
9.5
59
PF-06804103ERBB2
9.5
17.9
5.3
2.1
25.3
30.5
1.1
32.6
Brentuximab vedotinTNFRSF8
5
31
54
28
33
42
25
52
Disitamab vedotinERBB2
5
42.1
42.1
24.3
21.5
29
68.2
PF-06650808NOTCH3
5
12.5
15
2.5
20
40
10
Polatuzumab vedotinCD79B
1.2
26
60
32
68
42
1.7
53
DMOT4039AMSLN
0
12
17
37
19
Zilovertamab vedotinROR1
0
23
31.4
13
27.5
48
Glembatumumab vedotinGPNMB
0
11.7
39.4
16.9
44.1
36.2
Indusatumab vedotinGUCY2C
0
28.6
25
17.9
39.3
52.6
0
10.5
FOR-46CD46
0
21
70
30
39
45
ATG-022CLDN18
0
10.8
37.8
37.8
BYON-3521MET
0
29
3.2
EBC-129CEACAM5; CEACAM6
0
17
31
22
17
39
6
0%severity100%
0
Assessed · clear
true 0%
No data
never assessed